Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
messenger ribonucleic acid (spike protein)
- Development stage
- Preclinical
- Lead developer
- Factor Biosciences Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal, Subcutaneous, Oral, Inhalation, Intranasal, Transdermal
01
Overview
messenger ribonucleic acid (spike protein) is an mRNA-based vaccine candidate developed by Factor Biosciences Therapeutics for the prevention of COVID-19. The vaccine utilizes messenger RNA (mRNA) to encode the spike (S) protein of the SARS-CoV-2 virus. Upon administration, the mRNA is taken up by host cells and translated into the spike protein, which then acts as an antigen to stimulate a specific immune response, including the production of neutralizing antibodies and T-cell activation. This program leverages Factor Biosciences' proprietary mRNA synthesis and delivery platform, which is designed to optimize the expression and safety profile of mRNA therapeutics. The candidate is currently in the preclinical stage of development.
- Other names
- mRNA-based COVID-19 vaccineSARS-CoV-2 spike mRNA vaccineSARS-CoV2 spike mRNA vaccineSARS-CoV 2 spike mRNA vaccine
02
Targets
ACE2 (Angiotensin-converting enzyme 2)80S ribosome (Ribosome and ribosomal components)
Beyond the preview
Go deeper on messenger ribonucleic acid (spike protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on messenger ribonucleic acid (spike protein).